Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Prevalent AI Appoints Nitin Maini as CTO to Accelerate the Evolution of its AI-Powered Data Fabric
-
High Roller Technologies Announces ROLR™ Prediction Markets Platform Commercial Launch Timing
-
3 E Network Enters into $1M Private Placement to CEO-Led Entity at $1.426 Per Share
-
Transaction in Own Shares
-
Fixing of coupon rates - Nykredit Realkredit A/S
-
Pakistan Arrives at LEAP 2026 with Largest-Ever Delegation, Backing “Think Tech, Think Pakistan” with Scale
-
Corbin Advisors Wins First Gold Stevie® Award and Sixth Consecutive Employer of the Year Honor
-
Four Leaf Acquisition Corporation and Data443 Risk Mitigation, Inc. Advance Definitive Business Combination and Path to a Market Listing
-
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
-
Brixton Metals Drills 6,199 g/t Silver over 1.00 m including 0.50 m of 12,386 g/t Silver in Hole 432 at its Langis Project in Ontario
-
FuelCell Energy Reports Third Fiscal Quarter 2026 Results; Executes First Data Center Power Agreement, Increases Annualized Production Rate & Focuses on Capacity Expansion
-
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
-
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
-
Tema Photonics & Optical ETF (LAZR) Increases Anthropic Position Ahead of Highly Anticipated IPO
-
Algoma Steel Group Inc. Provides Update on Lake Superior Power Plant Outage
-
Cronos’ brand Spinach® Expands its Best-Selling Lineups of Edibles and Vapes
-
FuelCell Energy Reports Third Fiscal Quarter 2026 Results; Executes First Data Center Power Agreement, Increases Annualized Production Rate & Focuses on Capacity Expansion
-
Daktronics, Inc. Announces Fiscal 2027 First Quarter Results
-
BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
-
Farcast completes Telesat Lightspeed antenna technology demonstration milestone
-
Dyne Therapeutics to Participate in Upcoming Investor Conferences
-
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
-
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
-
Rezolute to Participate in Upcoming Investor Conferences
-
Zevra Therapeutics to Present at Upcoming Investor Conferences
-
OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor
-
Quantum Cyber Appoints Tzvi Lev as Head of Sales, Middle East to Lead GCC Commercial Expansion of Its Autonomous Defense Platform
-
Edible Garden Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
A Previously Unattested Egyptian Title and a Face from Roman Egypt: TimeLine’s 8 September Auction
-
The companies of CSG group will showcase their products at MSPO 2026, the largest trade fair of its kind in Central Europe
-
Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company
-
Kane Biotech Expands Canadian Commercial Reach with Ontario Medical Supply Inc.
-
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
-
Charles IT Expands AI and Automation Capabilities Through Acquisition of Descent
-
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
-
Taco Cabana Turns 48 With a Monthlong Celebration
-
Cardiff Oncology to Participate in September 2026 Conferences
-
MoneySimpler Unveils AI Automated Stock & Forex Trading to Boost Income for Social Security Benefits
-
G-III Apparel Group, Ltd. Reports Second Quarter Fiscal 2027 Results and Raises Earnings Guidance
-
Wallbridge Reports Results from 2026 Fenelon PFS Metallurgical Drilling Program
-
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
-
Newron announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
-
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
-
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
-
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
-
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
-
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
-
9/11 and Immigration Panel: 25 Years of Lessons and Unfinished Business
-
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
-
WRAP Moves to Operationalize De-Escalation, Advances New BolaWrap 150 Doctrine Toward California POST Certification
